| Ytd | -18.77% | |
| 1y | -21.47% |
| Open | 48.33 | Prev Close | 48.98 | Low | 47.25 | High | 48.60 | Mkt Cap | 8.55B |
| Vol | 673.27K | Avg Vol | 6.33M | EPS | -0.50 | P/E | -97.96 | Forward P/E | -576.54 |
| Beta | 3.46 | Short Ratio | 5.40 | Inst. Own | 57.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 51.40 | 200-d Avg | 61.44 | 1yr Est | 66.06 |
TEM News
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o
Tempus AI (NASDAQ: TEM) executives said the company's planned acquisition of Personalis is intended
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
On Monday, Tempus AI, Inc. (NASDAQ:TEM) agreed to acquire Personalis, Inc. (NASDAQ:PSNL), aiming to
Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full de
Amova Asset Management Americas Inc. raised its stake in Tempus AI, Inc. (NASDAQ: TEM) by 23.4% in t
Tempus AI Inc. (NASDAQ:TEM) investors have a decision to make. Shares of the precision medicine comp
Tempus AI stock has fallen about 16% YTD. Cathie Wood still owns it as ARKK's 4th largest holdin
Growth and chip stocks led a mixed Wall Street tape Monday as the S&P 500 and Nasdaq 100 rose wh
Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD
Tempus AI NASDAQ: TEM executives said the company's planned acquisition of Personalis is intended to
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholde
Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares
Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion,
Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer
Bristol Myers Squibb adopts NVIDIA DGX SuperPOD to train next-gen AI models and accelerate drug disc
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal dat
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o
Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion,
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precisi
Guggenheim analyst Subbu Nambi maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price t
Tempus AI, Inc. earns a Strong Buy rating due to its transformation into a healthcare data giant wit
Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearis
Lucid, Figma, SoundHound and Ondas are among the most heavily shorted stocks in the market right now
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
The stock portfolios of Nancy Pelosi and Donald Trump have at least 10 stocks in common. Here are th
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o
Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A de
Freedom Capital Markets analyst Gene Mannheimer initiates coverage on Tempus AI (NASDAQ:TEM) with
Tempus receives a Buy rating, leveraging a unique AI-driven diagnostics and data platform with expan
Nancy Pelosi has added stock or options in nine different companies since the start of 2025. A look
Angiosarcoma is a rare malignant tumor that starts in endothelial cells, which form the inner linin
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o
TEM's diagnostics growth and expanding data deals support momentum, but sizable GAAP losses and exec
Tempus AI (TEM) has consolidated near trend lows for four months, forming a double bottom with break
A selloff in high-flying chipmakers split Wall Street on Thursday, with Broadcom Inc. (NASDAQ:AVGO)‘
Dell beats massive estimates, IBM launches $5B Project Lightwell, CrowdStrike expands cyber insuranc
Bristol Myers Squibb expands AI efforts through Anthropic and Tempus partnerships as shares edge hig
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook
Large-cap stocks surged last week as catalysts from short squeezes to innovation-driven momentum fue
U.S. stocks were mixed at midday Wednesday as tech stocks rallied while industrials dragged the Dow
Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with dat
Tempus AI says ALERT trial shows higher valve procedures and faster care, while analysts keep a Buy
ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR
Cathie Wood's Ark Invest bought Tempus AI shares while trimming Meta, signaling a shift toward m
Mark Kelly emphasized the rapid workplace impact of artificial intelligence and called for "prac
Benzinga examined the prospects for many investors' favorite stocks over the last week — here